摘要
研究ATP结合盒(ABC)转运体ABCG2、ABCB5在多发性骨髓瘤(MM)RPMI-8226和NCI-H929细胞的表达及意义。方法:用实时定量反转录酶-聚合酶链锁反应(qRT-PCR)及蛋白印迹(Western blot)法检测MM细胞中ABCG2、AB-CB5的表达,并观察两株细胞在增殖、克隆、耐药及致瘤性等方面的差异。结果:qRT-PCR和Western blot显示AB-CG2、ABCB5均表达于RPMI-8226和NCI-H929细胞,且前者的表达水平较后者明显增高(P<0.05)。与NCI-H929细胞相比,增殖、克隆、耐药实验,RPMI-8226细胞增殖速度快、克隆形成能力强、对长春新碱的耐受性高(P<0.05)。成瘤实验显示第10周时RPMI-8226组鼠出现了肿瘤而NCI-H929组鼠始终未出现肿瘤。ABCG2、ABCB5高表达于RPMI-8226细胞,可能是其耐药性较NCI-H929细胞增高的机制之一。这将为MM细胞化疗药物的筛选和靶向耐药分子ABCG2、AB-CB5治疗MM提供实验依据。
To investigate expressions of ABC transporter ABCG2 and ABCB5 in the multiple myeloma（MM） RPMI-8226 andNCI-H929 cell lines and its significance, real time quantitative polymerase chain reaction （qRT-PCR）and Western blot（WB） methods were used to examine the expression levels of ABCG2 and ABCB5 in RPMI-8226 and NCI-H929 cells. Using CCK8 assay, clone formation in soft agar and MTT assay, we observed the biologic characteristic of RPMI-8226 and NCI-H929 cells, including the cellular proliferation activity, clonogenicity, drug resistance and tumorigenicity. ABCG2 and ABCB5 were expressed in both RPMI-8226 and NCI-H929 cells. The expressive levels of ABCG2 and ABCB5 in the RPMI-8226 cells was obvi- ously higher than that in the NCI-H929 cells （P〈0.05）. The RPMI-8226 cells＇ proliferation activity was significantly higher than that of NCI-H929 cells （P〈0.05）. As to the capabilities of both clonogenicity in soft agar and drug resistance, those of RPMI-8226 cells were stronger than that of NCI-H929 cells. The RPMI-8226 cells injected into the BALB/c nude mice had higher tumorigenicity than that of the NCI-H929 cells. The high expressions of ABCG2 and ABCB5 in RPMI-8226 cells implied that ABCG2 and ABCB5 may be associated with drug resistances. The study provides experiment evidence for the further targeting therapy of MM based on the molecules of ABCG2 and ABCB5.
出处
《现代免疫学》
CAS
CSCD
北大核心
2012年第6期479-483,共5页
Current Immunology
基金
江苏省研究生科研创新计划项目(CXZZ_0174)
东南大学优博基金项目(YBJJ1222)
